COVID-19: Mayo Clinic is committed to taking care of our patients, learners and staff. Learn more about guidelines for the resumption of live
(in-person) courses and conferences
effective July 1, 2021 and available COVID-19 online education and resources.



This series of 90-minute webinars features Mayo Clinic experts discussing monoclonal antibodies and other novel therapeutics in COVID-19 treatment. Webinar recordings will be available within 48 hours.

Previously Recorded ONLINE CME Course
Live Webinar - CLAIM CME CREDIT

Monoclonal Antibody Therapy Playbook: Mobilizing Teams, Managing Patients and Measuring Outcomes

On Wednesday, June 30, from 8:30 a.m. – 10:00 a.m. CDT, Mayo Clinic experts discuss logistics and practicalities in treating COVID-19 patients with monoclonal antibodies, as well as monitoring the effects of treatment.

  • Moderator: Nita Sharma, M.B.A., Associate Administrator, instructor in health care systems engineering
  • Featured expert: Jonathan A. Leighton, M.D., consultant, Division of Gastroenterology and Hepatology; professor of medicine
  • Featured expert: Marie (Jay) J. Maningo-Salinas, Ph.D., vice chair of research, Mayo Clinic in Arizona; assistant professor of nursing
  • Featured expert: Maria (Teresa) T. Seville, M.D., consultant, Division of Infectious Diseases; assistant professor of medicine
  • Featured expert: Christopher B. Grilli, Pharm.D., R.Ph., M.B.A., manager of pharmacy
  • Featured expert:  Penelope L. Heisler, R.N., O.C.N., supervisor of ambulatory infusion center

Previously Recorded - ONLINE CME Course
LIve Webinar - CLAIM CME CREDIT

“Black Fungus” in the Indian Subcontinent: Prevention and Cure

On Wednesday, June 23, from 8:30 a.m. – 10:00 a.m. CDT, Mayo Clinic experts discussed the probable causes of the COVID-19 associated rhino-orbital mucormycosis (“black fungus”) crisis in India, as well as therapeutic strategies for COVID-19 that can help to mitigate risks. In addition to medical and surgical treatment options, the role of monoclonal antibodies in high-risk patients will be addressed.

  • Moderator: Amit K. Ghosh, M.D., M.B.A., Consultant, Division of General Internal Medicine, Mayo Clinic; professor of medicine
  • Moderator: Devyani Lal, M.D., dean of education, Mayo Clinic in Arizona; chair, Division of Rhinology, Mayo Clinic in Arizona; professor of otolaryngology
  • Featured expert: Arun Kumar Agarwal, D.Sc., medical advisor, Innovation, Education and Clinical Excellence, Apollo Hospitals Group
  • Featured expert: Alok Thakar M.S., F.R.C.S., professor and chair, Department of Otolaryngology & Head-Neck Surgery, All India Institute of Medical Sciences, New Delhi
  • Featured expert: H. R. Vikram, M.D., consultant, Division of Infectious Diseases, Mayo Clinic in Arizona; professor of medicine

Previously Recorded - ONLINE CME COURSE
Live Webinar - CLAIM CME CREDIT

Monoclonal Antibody Therapy for COVID-19: What You Need to Know

On Wednesday, May 26, from 8:30 a.m. – 10:00 a.m. CDT, Mayo Clinic experts discussed monoclonal antibody treatment in depth, including what it is, how it works, and where it fits in the current treatment of COVID-19.

  • Moderator: Claudia R. Libertin, M.D., consultant, Division of Infectious Diseases; professor of medicine
  • Featured expert: Lisa Brumble, M.D., consultant, Division of Infectious Diseases; assistant professor of medicine
  • Featured expert: Kathleen (Kate) A. Rottman Pietrzak, Pharm.D., R.Ph., BCCCP, BCPS, clinical pharmacist; instructor in pharmacy
  • Featured expert: Leigh L. Speicher, M.D., M.P.H., consultant, Division of General Internal Medicine; assistant professor of medicine

Previously Recorded - ONLINE CME COURSE
Live Webinar - CLAIM CME CREDIT

Updates on Recently Authorized Therapies for COVID-19

On Wednesday, April 28, from 8:30 a.m. – 10:00 a.m. CDT, Mayo Clinic experts reviewed recently authorized therapies for COVID-19, including monoclonal antibody treatment and other novel therapeutics.

  • Moderator: Amit K. Ghosh, M.D., M.B.A., consultant, Division of General Internal Medicine; professor of medicine
  • Featured Expert: Raymund R. Razonable, M.D., FIDSA, FAST, vice chair, Division of Infectious Diseases; program director, Infectious Diseases Fellowship Program; professor of medicine
  • Featured Expert: Ravindra Ganesh, M.B.B.S., M.D., consultant, Division of General Internal Medicine; assistant professor of medicine
  • Featured Expert: Larry Lutwick, M.D., consultant, Division of Infectious Disease, Mayo Clinic Health System – Eau Claire; professor of medicine
  • Featured Expert: Lori Arndt, P.A.-C., Division of Infectious Diseases, Mayo Clinic Health System – Eau Claire
  • Featured Expert: Richard Arndt, Pharm.D., R.Ph., senior manager, Pharmacy Clinical Services, Mayo Clinic Health System – Eau Claire; assistant professor of pharmacy

Learning Objectives

Upon completion of this activity, you will be able to:

  • Explain the effect of neutralizing viral monoclonal bodies on the SARS-COV2 virus
  • Explain how mAb fit in the current paradigm of outpatient medical therapy of COVID-19
  • Explain contraindications for mAb and how to manage reactions and complications from mAb
  • Address logistical requirements for administration of mAb
  • Identify individuals at higher risk of disease progression that might benefit from early administration of mAb
  • Critically evaluate the impact of racial, ethnic, and socio-economic disparities in disease severity and access to optimal therapy for mild-moderate COVID-19
  • Detail logistical requirements from an HCP perspective: Supplies, personnel, training, developing nurse-initiated protocol and processes necessary for administration of mAb
  • Explain logistical requirements for healthcare administrators: Infrastructural needs, facilities management, personal deployment and training, in-facility safety protocols for mAb administration in COVID positive patients

Attendance at any Mayo Clinic course does not indicate or guarantee competence or proficiency in the skills, knowledge or performance of any care or procedure(s) which may be discussed or taught in this course.

Commercial Support

This educational activity is supported in part by an
independent medical education grant from

Eli Lilly and Company

and is in accordance with ACCME guidelines.